NYSE:BMYBristol-Myers Squibb Stock Price, Forecast & News

Bristol-Myers Squibb's stock was trading at $56.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BMY stock has increased by 5.2% and is now trading at $59.43. View which stocks have been most impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bristol-Myers Squibb.

Bristol-Myers Squibb is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Bristol-Myers Squibb.

Bristol-Myers Squibb will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Bristol-Myers Squibb Co (NYSE:BMY) posted its earnings results on Thursday, May, 7th. The biopharmaceutical company reported $1.72 EPS for the quarter, beating the consensus estimate of $1.49 by $0.23. The biopharmaceutical company earned $10.78 billion during the quarter, compared to analyst estimates of $10.04 billion. Bristol-Myers Squibb had a return on equity of 30.06% and a net margin of 3.08%. Bristol-Myers Squibb's quarterly revenue was up 82.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.10 EPS. View Bristol-Myers Squibb's earnings history.

Bristol-Myers Squibb declared a quarterly dividend on Thursday, June 11th. Shareholders of record on Monday, July 6th will be given a dividend of $0.45 per share on Monday, August 3rd. This represents a $1.80 annualized dividend and a yield of 3.03%. The ex-dividend date of this dividend is Thursday, July 2nd. View Bristol-Myers Squibb's dividend history.

Bristol-Myers Squibb updated its FY21 earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of $7.15-7.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.39.

14 analysts have issued 12 month price targets for Bristol-Myers Squibb's stock. Their forecasts range from $50.00 to $88.00. On average, they anticipate Bristol-Myers Squibb's stock price to reach $68.17 in the next twelve months. This suggests a possible upside of 14.7% from the stock's current price. View analysts' price targets for Bristol-Myers Squibb.

News coverage about BMY stock has been trending very negative on Thursday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bristol-Myers Squibb earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Bristol-Myers Squibb.

Some companies that are related to Bristol-Myers Squibb include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Bank of America (BAC), NVIDIA (NVDA), Intel (INTC), Johnson & Johnson (JNJ), Cisco Systems (CSCO) and CVS Health (CVS).

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Bristol-Myers Squibb's stock is owned by a number of institutional and retail investors. Top institutional investors include Thomasville National Bank (0.00%), Park National Corp OH (0.00%) and M&R Capital Management Inc. (0.00%). Company insiders that own Bristol-Myers Squibb stock include Adam Dubow, Dinesh C Paliwal, John E Elicker, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini and Theodore R Samuels II. View institutional ownership trends for Bristol-Myers Squibb.

BMY stock was sold by a variety of institutional investors in the last quarter, including M&R Capital Management Inc.. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Adam Dubow, John E Elicker, and Louis S Schmukler. View insider buying and selling activity for Bristol-Myers Squibb.

BMY stock was acquired by a variety of institutional investors in the last quarter, including Thomasville National Bank, and Park National Corp OH. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Robert J Bertolini, and Theodore R Samuels II. View insider buying and selling activity for Bristol-Myers Squibb.

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BMY stock can currently be purchased for approximately $59.43.

Bristol-Myers Squibb has a market capitalization of $134.47 billion and generates $26.15 billion in revenue each year. The biopharmaceutical company earns $3.44 billion in net income (profit) each year or $4.69 on an earnings per share basis. Bristol-Myers Squibb employs 30,000 workers across the globe.

The official website for Bristol-Myers Squibb is www.bms.com.

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]